[A20-93] Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Last updated 01.02.2021
Project no.:
A20-93
Commission:
Commission awarded on 02.11.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Adults with type 2 diabetes mellitus in 2 approved subindications (monotherapy and combination therapy)
Added benefit not proven for any of the 4 research questions
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A18-75 | Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-30 | Semaglutide (type 2 diabetes mellitus) - Addendum to Commission A20-93 | Commission completed |
Federal Joint Committee (G-BA)
2021.04.15 A G-BA decision was published.